One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
T Luger, JF Nicolas, M Brunori… - British Journal of …, 2014 - academic.oup.com
Background There are limited long‐term,'real‐world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …
One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe, T Luger… - British Journal of …, 2014 - infona.pl
Background There are limited long‐term,'real‐world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …
dose adjustment in suboptimal responders. Objectives We describe 52‐week data from …
[引用][C] One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized …
Z Adamski, G Altomare, M Aricò, N Aste… - BRITISH JOURNAL …, 2014 - research.unipd.it
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe… - British Journal of …, 2014 - abdn.elsevierpure.com
BACKGROUND: There are limited long-term,'real-world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. OBJECTIVES: We describe 52-week data from …
dose adjustment in suboptimal responders. OBJECTIVES: We describe 52-week data from …
[引用][C] One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized …
K REICH, L PUIG, M BRUNORI… - British journal of …, 2014 - pascal-francis.inist.fr
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching
from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe …
from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe …
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe… - The British journal …, 2014 - pubmed.ncbi.nlm.nih.gov
Background There are limited long-term,'real-world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe… - BRITISH JOURNAL …, 2014 - biblio.ugent.be
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from
inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque …
inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque …
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: The TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe… - British Journal of …, 2014 - portalrecerca.uab.cat
Background There are limited long-term,'real-world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …
[引用][C] One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized …
K Reich, L Puig, C Paul, K Kragballe, TA Luger… - 2014 - publications.goettingen-research …
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in …
K Reich, L Puig, C Paul, K Kragballe… - British Journal of …, 2014 - search.ebscohost.com
Background There are limited long-term,'real-world'data on ustekinumab, or the effect of
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …
dose adjustment in suboptimal responders. Objectives We describe 52-week data from …